Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease that is suitable for chemotherapy~* HER2-positive metastatic breast cancer (MBC)~* Left ventricular ejection fraction (LVEF) greater than or equal to (\>=) 55 percent (%) at baseline (within 42 days of randomization)~* Eastern Cooperative Oncology Group Performance Status of 0 or 1~* Women of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment (trastuzumab and/or pertuzumab)~Exclusion Criteria:~* History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC)~* History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting~* History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (\<) 12 months~* History of persistent Grade \>= 2 hematologic toxicity resulting from previous adjuvant therapy~* Grade \>= 3 peripheral neuropathy at randomization~* History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin carcinoma that has been previously treated with curative intent~* Current clinical or radiographic evidence of central nervous system (CNS) metastases~* History of exposure to cumulative doses of anthracyclines~* Current uncontrolled hypertension or unstable angina~* History of congestive heart failure (CHF) of any New York Heart Association (NYHA) classification, or serious cardiac arrhythmia requiring treatment~* History of myocardial infarction within 6 months of randomization~* History of LVEF decrease to \< 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy~* Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy~* Inadequate organ function within 28 days prior to randomization~* Current severe, uncontrolled systemic disease~* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment~* Pregnant or lactating women~* History of receiving any investigational treatment within 28 days of randomization~* Current known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or active hepatitis B virus (HBV)~* Receipt of intravenous (IV) antibiotics for infection within 14 days of randomization~* Current chronic daily treatment with corticosteroids (excluding inhaled steroids)~* Known hypersensitivity to any of the protocol-specified study treatments~* Concurrent participation in an interventional or noninterventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Placebo + Trastuzumab + Docetaxel (Type: ACTIVE_COMPARATOR): Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram \[mg/kg\] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter \[mg/m\^2\]) were administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
- Arm B: Pertuzumab + Trastuzumab + Docetaxel (Type: EXPERIMENTAL): Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m\^2) were administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete